---
document_datetime: 2023-09-21 18:06:07
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/kinzalmono-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: kinzalmono-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.3770863
conversion_datetime: 2025-12-19 21:23:20.034736
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

## For procedures finalised after 1 June 2002 please refer to module 8B.

- On  08  January  1999,  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  an application for Telmisartan Boehringer Ingelheim Pharma KG 20 mg tablets, under Annex II to Commission Regulation (EC) 542/95 as amended. The CPMP recommended the approval for this additional strength and adopted an opinion on 20 May 1999. The respective Commission Decision was issued on 07 September 1999.
- Pursuant to Article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992, the Marketing Authorisation Holder, notified the EMEA on 26 February 1999 of their intention to introduce changes to an aspect of the labelling not connect The Company requested additional changes on 8 March and 27 April 1999. (Changes to the Austrian contact address and the Danish contact fax number have been introduced. The section 'Storage conditions' of the package leaflet has been amended in order to be consistent with the section  'Special  precautions  for  storage'  of  the  SPC.  Linguistic  corrections  have  been implemented into the German and Greek package leaflet.). On 30 April 1999, the EMEA hereby informs  the  European  Commission  that  the  above-mentioned  changes  are  accepted.  The respective Commission Decision was issued on 03 June 1999.
- The Marketing Authorisation Holder submitted to the EMEA on 8 March 1999 an application for  one  type  I  variation  falling  within  the  scope  of  item  No.  15  of  Annex  I  to  Commission Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for:

Several  minor  changes  to  the  manufacturing  process  of  the  finished  product,  including  an increase in batch size.

On  19  April  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require amendments to the Commission Decision.

- The Marketing Authorisation Holder submitted to the EMEA on 8 March 1999 an application for  one  type  I  variation  falling  within  the  scope  of  item  No.  1  of  Annex  I  to  Commission Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for:

A change in the sites of the manufacture of spray-dried granulate.

On  19  April  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require amendments to the Commission Decision.

- The Marketing Authorisation Holder submitted to the EMEA, between 6 September 1999 and 19 November 1999, a number of applications for one type I variation falling within the scopes of item No 1, 12a, 14, 24a and 32 of Annex I to Commission Regulation (EC) No 542/95, as amended.  The Marketing Authorisation Holder applied for:
- -Change of the manufacturing sites for part of the manufacturing process of the medicinal product.
- -Change of imprints, bossing or other markings (except scoring) on tablets.
- -Change in specification of starting material or intermediate used in the manufacture of the active substance (with Change in specification of active substance).
- -Changes in test procedure for starting material or intermediate used in the manufacture of the active substance.

Between  29  October  1999  and  15  March  2000,  the  EMEA  issued  the  corresponding notifications. These variations did not require amendments to the Commission Decision.

- The Marketing Authorisation Holder submitted to the EMEA on November 1999 an application of  one  type  I  variation  falling  within  the  scope  of  item  No  20  of  Annex  I  to  Commission Regulation (EC) No 542/95, as amended.  The Marketing Authorisation Holder applied for:

An extension of shelf-life.

<div style=\"page-break-after: always\"></div>

On 17 December 1999, the EMEA issued the corresponding notification. The variation required amendments in the relevant sections of the Commission decision. The respective Commission Decision was issued on 09 March 2000.

- Pursuant to Article 10(3) of Council Directive No. 92/27/EEC of 31 March 1992, the Marketing Authorisation  Holder,  notified  the  EMEA  on  9  February  2000  of  their  intention  to  introduce changes to an aspect of the labelling of the 20 mg strength not connected to the Summary of Product Characteristic. Changes were related to the list of Marketing Authorisation representatives  or  were  of  linguistic  nature.  On  21  February  2000,  the  EMEA  issued  the corresponding notification. The respective Commission Decision was issued on 30 March 2000.
- On  31 st January  2000,  the  Marketing  Authorisation  Holder  submitted  a  Type  II  variation application  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10 March 1995, as amended.  The scope of the variation related to the update of the SPC and PL of the 40 and 80 mg strengths to put them in line with the SPC and PL of the recently approved 20 mg strength and with the latest QRD SPC/labelling/PL templates. In addition, the list has been updated.  During  the  assessment,  sections  on  pregnancy  and  interaction  with  food  have  been revised in order to be more accurate.

On 12 April 2000, the CPMP approved the variation. The variation required amendments in the relevant  sections  of  the  Commission  Decision  and  the  EPAR.  The  European  commission amended the Decision on 13 July 2000.

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                                           | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amended on   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|-----------------------------------------|
| Minor change of manufacturing process of the active substance With consequential change in test procedure for starting material/intermediate used in manuf. of active substance | I/0016               | I                        | 02.08.00                            | N/A                                     |
| Batch size of active substance                                                                                                                                                  | I/0017               | I                        | 02.08.00                            | N/A                                     |
| Change in test procedures of the medicinal product                                                                                                                              | I/0018               | I                        | 14.08.00                            | N/A                                     |
| Changes in manufacture of the medicinal product                                                                                                                                 | I/0019               | I                        | 22.09.00                            | N/A                                     |
| Update of Summary of Product Characteristics and Package Leaflet The SPC was updated following the assessment of the 2 nd and 3 rd PSUR.                                        | II/0020              | II                       | 19.10.00                            | 22.01.01                                |
| Replacement of an excipient with a comparable excipient                                                                                                                         | I/0021               | I                        | 04.05.01                            | N/A                                     |
| Extension of shelf-life as foreseen at time of authorisation                                                                                                                    | I/0022               | I                        | 22.08.01                            | 19.10.01                                |
| Change in pack size for a medicinal product for 40 mg and 80 mg presentations.                                                                                                  | I/0023               | I                        | 23.08.01                            | 19.10.01                                |
| Update of the SPC and PL (point 4.4, 4.5, 4.8)                                                                                                                                  | II/0024              | II                       | 23.05.02                            | 30.05.02                                |

1 In  accordance  with  Commission Regulation (EC) No.  542/95 of 10 March 1995, as amended: I refers  to  a minor  variation  (Type  I  variation); II refers  to  a  major  variation  (Type  II  variation); I/II refers  to  a  minor variation  following  the  procedure  set  out  in  Article  6,  7  and  8  of  the  Regulation; X refers  to  an  Annex  II application.

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.